FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing

Approved proteasome inhibitors have advanced the treatment of multiple myeloma but are associated with serious toxicities, poor pharmacokinetics, and most with the inconvenience of intravenous administration. We therefore sought to identify novel orally bioavailable proteasome inhibitors with a cont...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cell Death Dis
Asıl Yazarlar: Wang, Z, Dove, P, Wang, X, Shamas-Din, A, Li, Z, Nachman, A, Oh, Y J, Hurren, R, Ruschak, A, Climie, S, Press, B, Griffin, C, Undzys, E, Aman, A, Al-awar, R, Kay, L E, O'Neill, D, Trudel, S, Slassi, M, Schimmer, A D
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2015
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4650734/
https://ncbi.nlm.nih.gov/pubmed/26158521
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cddis.2015.187
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller